Compounds > ethylphenylhydantoin
Page last updated: 2024-12-07

ethylphenylhydantoin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

ethylphenylhydantoin: the name nirvanol may have been used for ethotoin; RN given refers to cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID91480
CHEMBL ID1438
CHEBI ID79441
SCHEMBL ID2191989
MeSH IDM0063117

Synonyms (65)

Synonym
HMS1680D20
AC-16032
5-ethyl-5-phenylimidazolidine-2,4-dione
STL309598
5-ethyl-2-hydroxy-5-phenyl-1,5-dihydro-4h-imidazol-4-one
2,4-imidazolidinedione, 5-ethyl-5-phenyl-
2216-93-5
nsc-33388
nsc33388
OPREA1_683047
5-ethyl-5-phenyl-2,4-imidazolidinedione
einecs 211-150-3
nsc 150466
desmethylmephenytoin
nsc 33388
2,4-imidazolidinedione, 5-ethyl-5-phenyl-, (+-)-
hydantoin, 5-ethyl-5-phenyl-, (+-)-
(+-)-nirvanol
normephenytoin
(+-)-5-ethyl-5-phenylhydantoin
OPREA1_300355
5-ethyl-5-phenyl-imidazolidine-2,4-dione
5-phenyl-5-ethylhydantoin
nsc150466
nirvanol
2, 5-ethyl-5-phenyl-
5-ethyl-5-phenylhydantoin
631-07-2
hydantoin, 5-ethyl-5-phenyl-
nsc-150466
ethylphenylhydantoin
NCGC00165925-01
chebi:79441 ,
CHEMBL1438
AKOS000263617
FT-0666170
FT-0666172
FT-0666169
A834217
STK285748
EN300-04353
23sm1fa1ak ,
unii-23sm1fa1ak
FT-0641025
(+/-)-5-ethyl-5-phenylhydantoin
(+/-)-nirvanol
(rs)-5-ethyl-5-phenyl-2,4-imidazolidinedione
rac n-desmethyl mephenytoin
FT-0632677
AKOS022104892
(+/-)-5-ethyl-5-phenyl-imidazolidine-2,4-dione
5-ethyl-5-phenyl-hydantoin
AKOS016046645
SCHEMBL2191989
F0239-0674
J-650236
mfcd00022401
5-ethyl-5-phenyl-1h-imidazolidin-2,4-dione
J-517475
sr-01000317290
SR-01000317290-1
Z56757176
DTXSID80874185
Q7040139
5-ethyl-5-phenyl-1h-imidazole-2,4(3h,5h)-dione

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" The l-form exhibited a longer plasma half-life (23."( Stereoselective metabolism, pharmacokinetics and biliary elimination of phenylethylhydantoin (Nirvanol) in the dog.
Bircher, J; Küpfer, A; Preisig, R, 1977)		0.26
"Disposition of 1-benzenesulfonyl-5,5-diphenylhydantoin (II) having a potent anti-inflammatory activity was compared with that of 5,5-diphenylhydantoin (I), an antiepileptic drug, in order to elucidate whether the pharmacodynamic difference between them can be explained by their physicochemical and pharmacokinetic properties."( Biopharmaceutical studies on hydantoin derivatives. V. Pharmacokinetics and pharmacodynamics of 5,5-diphenylhydantoin and 1-benzenesulfonyl-5,5-diphenylhydantoin.
Fujioka, H; Kishi, M; Masuda, Y; Miyazaki, H; Tan, T; Yokoyama, Y, 1986)		0.27
" These data indicate that pharmacodynamic results obtained with cultured hepatocytes represent a good qualitative and quantitative approximation of the in vivo hepatic responses in male rats caused by PB-type inducers."( Pharmacodynamics of cytochrome P450 2B induction by phenobarbital, 5-ethyl-5-phenylhydantoin, and 5-ethyl-5-phenyloxazolidinedione in the male rat liver or in cultured rat hepatocytes.
Jones, CR; Lubet, RA; Mellini, DW; Nims, RW; Sinclair, JF; Sinclair, PR; Syi, JL; Thomas, PE, )		0.13

Dosage Studied

ExcerptRelevanceReference
" In fact, the response to PB-type inducers in male or female Zucker rats is probably most clearly explained as a shift of the dose-response curve sharply to the right (decreased responsiveness, compared to F344/NCr or DA rats of the same sex)."( A markedly diminished pleiotropic response to phenobarbital and structurally-related xenobiotics in Zucker rats in comparison with F344/NCr or DA rats.
Devor, DE; Diwan, BA; Dragnev, KH; Jones, CR; Lubet, RA; Miller, MS; Nims, RW; Rice, JM; Ward, JM, 1992)		0.28
" Dose-response experiments performed with 5-ethyl-5-phenylhydantoin indicated that the intrinsic CYP2B-inducing activity of this congener was as great as that of phenobarbital in the mouse, although a fourfold greater dietary concentration of this hydantoin (2000 ppm) was required to elicit a response equivalent to that caused by 500 ppm phenobarbital."( Hepatic cytochrome P450 2B induction by ethyl/phenyl-substituted congeners of phenobarbital in the B6C3F1 mouse.
Diwan, BA; Lubet, RA; Mellini, DW; Nims, RW; Thomas, PE; Utermahlen, WE, 1994)		0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
imidazolidine-2,4-dioneAn imidazolidinone with oxo groups at position 2 and 4.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID282040Displacement of [3H]BTX-B from voltage gated sodium channel in rat cerebral cortex synaptoneurosomes2004Journal of medicinal chemistry, Dec-16, Volume: 47, Issue:26
Synthesis and structure-activity relationship studies for hydantoins and analogues as voltage-gated sodium channel ligands.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (33)

TimeframeStudies, This Drug (%)All Drugs %
pre-199018 (54.55)18.7374
1990's6 (18.18)18.2507
2000's7 (21.21)29.6817
2010's2 (6.06)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.44

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.44 (24.57)
Research Supply Index3.74 (2.92)
Research Growth Index4.18 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.44)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (2.44%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other40 (97.56%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
coumarin
2H-chromen-2-one: coumarin derivative		1.9910coumarinsfluorescent dye;
human metabolite;
plant metabolite
imidazole
imidazole: RN given refers to parent cpd. 1H-imidazole : An imidazole tautomer which has the migrating hydrogen at position 1.		2.6230imidazole
pyridine
azine : An organonitrogen compound of general structure RCH=N-N=CHR or RR'C=N-N=CRR'.		1.9710azaarene;
mancude organic heteromonocyclic parent;
monocyclic heteroarene;
pyridines		environmental contaminant;
NMR chemical shift reference compound
phenytoin
[no description available]		3.0850imidazolidine-2,4-dioneanticonvulsant;
drug allergen;
sodium channel blocker;
teratogenic agent
barbital
5,5-diethylbarbituric acid : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by two ethyl groups. Formerly used as a hypnotic (sleeping aid).		2.6630barbituratesdrug allergen
debrisoquin
Debrisoquin: An adrenergic neuron-blocking drug similar in effects to GUANETHIDINE. It is also noteworthy in being a substrate for a polymorphic cytochrome P-450 enzyme. Persons with certain isoforms of this enzyme are unable to properly metabolize this and many other clinically important drugs. They are commonly referred to as having a debrisoquin 4-hydroxylase polymorphism.		3.4720carboxamidine;
isoquinolines		adrenergic agent;
antihypertensive agent;
human metabolite;
sympatholytic agent
ethotoin
ethotoin: was heading 1966-94 (see under HYDANTOINS 1966-90); use HYDANTOINS to search ETHOTOIN 1966-94. ethotoin : An imidazolidine-2,4-dione that is hydantoin substituted by ethyl and phenyl at positions 3 and 5, respectively. An antiepileptic, it is less toxic than phenytoin but also less effective.		2.8440imidazolidine-2,4-dioneanticonvulsant
mephenytoin
Mephenytoin: An anticonvulsant effective in tonic-clonic epilepsy (EPILEPSY, TONIC-CLONIC). It may cause blood dyscrasias.. mephenytoin : An imidazolidine-2,4-dione (hydantoin) in which the imidazolidine nucleus carries a methyl group at N-3 and has ethyl and phenyl substituents at C-5. An anticonvulsant, it is no longer available in the USA or the UK but is still studied largely because of its interesting hydroxylation polymorphism.		5.8300imidazolidine-2,4-dioneanticonvulsant
phenobarbital
Phenobarbital: A barbituric acid derivative that acts as a nonselective central nervous system depressant. It potentiates GAMMA-AMINOBUTYRIC ACID action on GABA-A RECEPTORS, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations.. phenobarbital : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by ethyl and phenyl groups.		3.0750barbituratesanticonvulsant;
drug allergen;
excitatory amino acid antagonist;
sedative
diethylnitrosamine
Diethylnitrosamine: A nitrosamine derivative with alkylating, carcinogenic, and mutagenic properties.. N-nitrosodiethylamine : A nitrosamine that is N-ethylethanamine substituted by a nitroso group at the N-atom.		1.9710nitrosaminecarcinogenic agent;
hepatotoxic agent;
mutagen
mephobarbital
Mephobarbital: A barbiturate that is metabolized to PHENOBARBITAL. It has been used for similar purposes, especially in EPILEPSY, but there is no evidence mephobarbital offers any advantage over PHENOBARBITAL.. mephobarbital : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at N-1 by a methyl group and at C-5 by ethyl and phenyl groups.		3.0610barbituratesanticonvulsant
hydantoins
Hydantoins: Compounds based on imidazolidine dione. Some derivatives are ANTICONVULSANTS.. imidazolidine-2,4-dione : An imidazolidinone with oxo groups at position 2 and 4.		5.3180imidazolidine-2,4-dione
hydroxyphenytoin
hydroxyphenytoin: main metabolite of diphenylhydantoin; reduces Na(+) inhibition at high Na:K ratios; RN given refers to cpd without isomeric designation; structure. 4-hydroxyphenytoin : A imidazolidine-2,4-dione that consists of hydantoin bearing phenyl and 4-hydroxyphenyl substituents at position 5.		2.0410imidazolidine-2,4-dione;
phenols		metabolite
5,5-diethylhydantoin
5,5-diethylhydantoin: RN given refers to unlabeled parent cpd		1.9710
pc-796
[no description available]		1.9610
4-hydroxymephenytoin
4-hydroxymephenytoin: metabolite of mephenytoin; RN given refers to cpd without isomeric designation		2.9140imidazolidine-2,4-dione
troleandomycin
Troleandomycin: A macrolide antibiotic that is similar to ERYTHROMYCIN.. troleandomycin : A semi-synthetic macrolide antibiotic obtained by acetylation of the three free hydroxy groups of oleandomycin. Troleandomycin is only found in individuals that have taken the drug.		1.9910acetate ester;
epoxide;
macrolide antibiotic;
monosaccharide derivative;
polyketide;
semisynthetic derivative		EC 1.14.13.97 (taurochenodeoxycholate 6alpha-hydroxylase) inhibitor;
xenobiotic
dinoprostone
prostaglandin E2 : Prostaglandin F2alpha in which the hydroxy group at position 9 has been oxidised to the corresponding ketone. Prostaglandin E2 is the most common and most biologically potent of mammalian prostaglandins.		1.9610prostaglandins Ehuman metabolite;
mouse metabolite;
oxytocic
warfarin
Warfarin: An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.. warfarin : A racemate comprising equal amounts of (R)- and (S)-warfarin. Extensively used as both an anticoagulant drug and as a pesticide against rats and mice.. 4-hydroxy-3-(3-oxo-1-phenylbutyl)-1-benzopyran-2-one : A member of the class of coumarins that is 4-hydroxycoumarin which is substituted at position 3 by a 1-phenyl-3-oxo-1-butyl group.		1.9910benzenes;
hydroxycoumarin;
methyl ketone
ConditionIndicatedRelationship StrengthStudiesTrials
Encephalitis, Polio
[description not available]		02.0610
Poliomyelitis
An acute infectious disease of humans, particularly children, caused by any of three serotypes of human poliovirus (POLIOVIRUS). Usually the infection is limited to the gastrointestinal tract and nasopharynx, and is often asymptomatic. The central nervous system, primarily the spinal cord, may be affected, leading to rapidly progressive paralysis, coarse FASCICULATION and hyporeflexia. Motor neurons are primarily affected. Encephalitis may also occur. The virus replicates in the nervous system, and may cause significant neuronal loss, most notably in the spinal cord. A rare related condition, nonpoliovirus poliomyelitis, may result from infections with nonpoliovirus enteroviruses. (From Adams et al., Principles of Neurology, 6th ed, pp764-5)		02.0610
Sensitivity and Specificity
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)		02.7130
Cataract, Membranous
[description not available]		01.9310
Eye Disorders
[description not available]		01.9310
Cataract
Partial or complete opacity on or in the lens or capsule of one or both eyes, impairing vision or causing blindness. The many kinds of cataract are classified by their morphology (size, shape, location) or etiology (cause and time of occurrence). (Dorland, 27th ed)		01.9310
Eye Diseases
Diseases affecting the eye.		01.9310
Keratitis
Inflammation of the cornea.		01.9310
Abdominal Epilepsy
[description not available]		01.9610
Epilepsies, Partial
Conditions characterized by recurrent paroxysmal neuronal discharges which arise from a focal region of the brain. Partial seizures are divided into simple and complex, depending on whether consciousness is unaltered (simple partial seizure) or disturbed (complex partial seizure). Both types may feature a wide variety of motor, sensory, and autonomic symptoms. Partial seizures may be classified by associated clinical features or anatomic location of the seizure focus. A secondary generalized seizure refers to a partial seizure that spreads to involve the brain diffusely. (From Adams et al., Principles of Neurology, 6th ed, pp317)		01.9610
Pregnancy
The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.		01.9610
Body Weight
The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.		01.9710
Experimental Hepatoma
[description not available]		01.9710
Cancer of the Thyroid
[description not available]		01.9710
Thyroid Neoplasms
Tumors or cancer of the THYROID GLAND.		01.9710